PUBLISHER: DelveInsight | PRODUCT CODE: 1226645
PUBLISHER: DelveInsight | PRODUCT CODE: 1226645
"ZEPOSIA Market Drug Insight and Market Forecast - 2032" report provides comprehensive insights about ZEPOSIA for Ulcerative Colitis (UC) in the seven major markets. A detailed picture of the ZEPOSIA for ulcerative colitis in the 7MM, i.e., the United States, EU4 (Germany, France, Italy and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the ZEPOSIA for ulcerative colitis. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the ZEPOSIA market forecast analysis for ulcerative colitis in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in ulcerative colitis.
ZEPOSIA (Ozanimod; RPC1063) has been developed by Celgene for the treatment of Inflammatory Bowel Disease (including both CD and UC). ZEPOSIA contains Ozanimod, an S1P receptor modulator, and is supplied as Ozanimod hydrochloride (HCl). Ozanimod is a sphingosine 1-phosphate (S1P) receptor modulator that binds with high affinity to S1P receptors one and five. Ozanimod blocks the capacity of lymphocytes to egress from lymph nodes, reducing the number of lymphocytes in peripheral blood. The mechanism by which Ozanimod exerts therapeutic effects is unknown but may involve the reduction of lymphocyte migration into the central nervous system.
Dosage
The recommended maintenance dosage is 0.92 mg orally once daily. If a dose is missed within the first 2 weeks of treatment, reinitiate the titration regimen. If a dose is missed after the first 2 weeks of treatment, continue treatment as planned.
Mechanism of action
Ozanimod is a sphingosine 1-phosphate (S1P) receptor modulator that binds with high affinity to S1P receptors one and five. Ozanimod blocks the capacity of lymphocytes to egress from lymph nodes, reducing the number of lymphocytes in peripheral blood. Ozanimod has minimal or no activity on S1P2, S1P3, and S1P4. The mechanism by which ozanimod exerts therapeutic effects in multiple sclerosis and UC is unknown but may involve the reduction of lymphocyte migration into the central nervous system and intestine.
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
ZEPOSIA Analytical Perspective by DelveInsight
This report provides a detailed market assessment of ZEPOSIA for ulcerative colitis in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.
The report provides the clinical trials information of ZEPOSIA for ulcerative colitis covering trial interventions, trial conditions, trial status, start and completion dates.
Key Questions